Peter García

Directeur Financier/CFO chez Bluejay Therapeutics, Inc.

Profil

Peter S.
García currently works at Moraga Biotechnology Corp., as Director and Bluejay Therapeutics, Inc., as Chief Financial Officer from 2024.
Mr. García also formerly worked at Noden Pharma USA, Inc., as Director, DURECT Corp., as Independent Director from 2021 to 2025, Amgen, Inc., as Principal, MDRNA, Inc., as Chief Financial Officer & Secretary in 2010, Lineage Cell Therapeutics, Inc., as CFO, Head-Investor & Media Relations from 2012 to 2013, Nuvelo, Inc., as Chief Financial Officer & Senior Vice President from 2001 to 2004, IntraBiotics Pharmaceuticals, Inc., as Chief Financial Officer from 1996 to 2004, Dendreon Corp., as Chief Financial Officer from 1996 to 2004, CYTYC Surgical Products, as Chief Financial Officer, Nanosys, Inc., as Chief Financial Officer from 2004 to 2008, Asterias Biotherapeutics, Inc., as Chief Financial Officer, Teradata Corp., as Principal, PDL BioPharma, Inc., as Chief Financial Officer & Vice President from 2013 to 2019, Adhera Therapeutics, Inc., as Chief Financial Officer, Secretary & IR Contact in 2011, Novacept, Inc., as Chief Financial Officer, and ALX Oncology Holdings, Inc., as Chief Financial Officer from 2021 to 2024.
Mr. García received his undergraduate degree in 1983 from Stanford University and Masters Business Admin degree in 1985 from the University of California, Los Angeles.

Postes actifs de Peter García

Sociétés	Poste	Début
Moraga Biotechnology Corp.	Directeur/Membre du Conseil	11/05/2011
Bluejay Therapeutics, Inc.	Directeur Financier/CFO	01/11/2024

Anciens postes connus de Peter García

Sociétés	Poste	Fin
DURECT	Directeur/Membre du Conseil	11/09/2025
ALX ONCOLOGY HOLDINGS INC.	Directeur Financier/CFO	08/11/2024
PDL BIOPHARMA, INC.	Directeur Financier/CFO	15/08/2019
LINEAGE CELL THERAPEUTICS, INC.	Directeur Financier/CFO	10/05/2013
ADHERA THERAPEUTICS, INC.	Directeur Financier/CFO	08/09/2011